Related Experiment Video

Updated: Dec 17, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.0K

Dopamine and cAMP-regulated phosphoprotein 32kDa (DARPP-32), protein phosphatase-1 and cyclin-dependent kinase 5

Stewart G Martin1, Siwei Zhang1, Song Yang1

  • 1Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK.

Journal of Cellular and Molecular Medicine
|June 27, 2020
PubMed

Insights

Low expression of Dopamine and cyclic-AMP activated phosphoprotein Mr32kDa (DARPP-32) correlates with poorer outcomes in ovarian cancer. DARPP-32, PP1, and Cdk5 may serve as prognostic markers for this disease.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Oncology

Background:

  • Dopamine and cyclic-AMP activated phosphoprotein Mr32kDa (DARPP-32) is a key signaling protein in neurotransmission.
  • DARPP-32 regulates protein kinase A (PKA) and protein phosphatase 1 (PP1) activity.
  • The role of DARPP-32 in ovarian cancer is not well understood.

Purpose of the Study:

  • To investigate the expression of DARPP-32, PP1, and cyclin-dependent kinase 5 (Cdk5) in ovarian cancer.
  • To evaluate the association between the expression of these proteins and patient clinical outcomes.
  • To determine the potential of these proteins as prognostic markers in ovarian cancer.

Main Methods:

  • Immunohistochemistry was used to assess the expression of DARPP-32, PP1, and Cdk5 in a cohort of 428, 445, and 434 primary ovarian tumors, respectively.
  • Statistical analyses, including univariate and multivariate Cox regression, were performed to correlate protein expression with overall survival and progression-free survival.

Main Results:

  • Low cytoplasmic and nuclear DARPP-32 expression was significantly associated with shorter overall survival and progression-free survival.
  • High cytoplasmic and nuclear PP1 expression correlated with shorter overall survival, and high cytoplasmic PP1 with shorter progression-free survival.
  • High Cdk5 expression was linked to shorter progression-free survival.

Conclusions:

  • DARPP-32, PP1, and Cdk5 expression levels are associated with clinical outcomes in ovarian cancer patients.
  • These proteins may serve as valuable prognostic biomarkers for ovarian cancer.
  • Further research into the signaling pathways involving DARPP-32 in ovarian cancer is warranted.
Keywords:
Cdk5DARPP-32PKAPP1ovarian cancerprognosis

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.1K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.6K

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
132.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K